Plain-English translation of NCT06704152 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing BSB-1001, a new treatment made from immune cells that have been genetically modified to recognize and attack cancer cells. The treatment is given to patients with acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome who are undergoing a stem cell transplant from a matched donor. The goal is to help prevent the cancer from coming back after transplant.
After a stem cell transplant, blood cancers can sometimes return. This medication is designed to give the new immune system an extra boost to find and destroy any remaining cancer cells that might cause a relapse.
You likely qualify if…
You likely don't qualify if…
You would receive intensive chemotherapy or radiation to prepare your body for the stem cell transplant, then receive the transplant itself on day 0, followed immediately by an infusion of the engineered immune cells. After that, you would be closely monitored in the hospital and then as an outpatient for safety, with regular blood tests and clinical visits to track how well the treatment is working and to watch for any side effects.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States